Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Bronchiolo-alveolar adenocarcinoma; Large cell carcinoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms I-SABR
- 07 Feb 2019 Planned End Date changed from 1 Jun 2022 to 30 Jun 2022.
- 07 Feb 2019 Planned primary completion date changed from 1 Jun 2022 to 30 Jun 2022.
- 04 Oct 2018 Planned End Date changed from 1 Jun 2023 to 1 Jun 2022.